Form 15-12G Day One Biopharmaceutica
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-40431
DAY ONE BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
1800 Sierra Point Parkway, Suite 200
Brisbane, CA 94005
Telephone: (650) 484-0899
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Common stock, $0.0001 par value per share
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
| Rule 12g-4(a)(1) |
☒ | |
| Rule 12g-4(a)(2) |
☐ | |
| Rule 12h-3(b)(1)(i) |
☒ | |
| Rule 12h-3(b)(1)(ii) |
☐ | |
| Rule 15d-6 |
☐ | |
| Rule 15d-22(b) |
☐ |
Approximate number of holders of record as of the certification or notice date: One holder
Pursuant to the requirements of the Securities Exchange Act of 1934, Day One Biopharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
| Date: May 4, 2026 | Day One Biopharmaceuticals, Inc. | |||||
| By: | /s/ David Lee | |||||
| Name: | David Lee | |||||
| Title: | President and Secretary | |||||
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Click Bond Welcomes Nathan Delgleize as New VP, Finance
- OpenVC™ Announces Close of OPEN Unicorn Fund, Expanding Access to Private Market Leaders
- SEC Appoints Kathleen Hutchinson as Director of Office of International Affairs
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share